Furthermore, our studies revealed that SFRP2 is a potential biomarker for the diagnosis of early-stage ovarian cancer with considerable AUC value and is associated with poor survival rates of OC patients in stages II-IV. This evidence concerns the gene SFRP2 and ovarian cancer.